|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SynNotch receptors induced ROR1 CAR expression selectively within the tumor, resulting in tumor regression without toxicity when tumor cells were segregated from, but not when co-localized with, normal ROR1<sup>+</sup> cells.
|
30889382 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ad-mTNFa-mIL2 increased both CAR T cell and host T cell infiltration to the tumor and altered host tumor immune status with M1 polarization of macrophages and increased dendritic cell maturation.
|
29618658 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-T) cell has shown a promising future.
|
30721445 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Human T cells expressing CAR targeting mesothelin or fibroblast activation protein and containing CD3ζ and 4-1BB cytoplasmic domains were intravenously injected into immunodeficient mice bearing large, established human mesothelin-expressing flank tumors.
|
24919573 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In immunocompetent orthotopic mouse models of pancreatic cancer and melanoma, we found that CAR T cells can migrate from biopolymer scaffolds and eradicate tumors more effectively than does systemic delivery of the same cells.
|
28436934 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Advancing the use of adoptively transferred T cells for the treatment of patients with solid tumor and other hematologic malignancies however, will require addressing numerous effector cell intrinsic as well as tumor micro environmental hurdles and exploiting a broader ACT platform that includes not only engineered CAR-T cells, but also other forms of ACT including Endogenous T Cell (ETC) and Tumor-infiltrating Lymphocyte (TIL) therapy.
|
29730057 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Intratumoral injection of the Ad.Lp-CD-IRES-E1A(MRGD) vector following the intraperitoneal injection of 5FC into xenotransplanted human breast cancer cell lines which have low expression level of CAR led to greater degree of tumor regression in vivo than did the intratumoral injection of control adenoviral vectors not so modified.
|
16179927 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Researchers increased the effectiveness of CAR T-cell therapy in solid tumors by injecting the cells near the tumors.
|
25583818 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we engineered T cells with a CAR consisting of the extracellular domain of heregulin-1β (HRG1β) that is a natural ligand for HER3/HER4, and evaluated the specific cytotoxicity of these CAR-T cells in cultured HER3 positive breast cancer cells and xenograft tumors.
|
29127433 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrate that both switch formats can be readily optimized to redirect CAR-T cells (specific for the corresponding FITC or PNE) to Her2-expressing tumor cells, and afford dose-titratable activation of CAR-T cells ex vivo and complete clearance of the tumor in rodent xenograft models.
|
27145250 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have explored the benefits of incorporating the IL15 cytokine within the CAR cassette to provide both a survival signal before antigen encounter, and an additional cytokine signaling at the tumor site using a neuroblastoma tumor model.
|
30617136 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review we discuss some of the mechanistic contributions intrinsic to the CAR-T construct, the tumor being treated, and the individual patient that impact the development and severity of CRS and neurotoxicity.
|
31355491 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors <i>in vivo</i>.
|
30651858 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The cells were incubated with Raji cells and the LDH test was performed to detect the cytotoxic effect of CAR-T cells; the tumor volume and survival rate were measured to observe its inhibitory effect on B cell lymphoma in nude mice.
|
26195067 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing.
|
31114587 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive T cell transfer therapy (ACT) using tumor infiltrating lymphocytes or lymphocytes redirected with antigen receptors (CAR or TCR) has revolutionized the field of cancer immunotherapy.
|
30842774 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In in vivo experiment, we confirmed how DOC enhanced the recruitment of HER2-CAR T cells to tumor sites.
|
30744691 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, their broad use is limited since a CAR targets a single tumor associated antigen (TAA), which is not effective against tumors with heterogeneous TAA expression or emerging antigen loss variants.
|
30984613 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, the CAR-T cells inhibited growth of cell-line- and patient-derived xenograft TNBC tumors in mice.
|
31804974 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Autologous CAR T cells are generated from the patient's peripheral blood T cells and expand in the recipient to eliminate the targeted tumor.
|
29245005 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR T cells lacking all three NR4A transcription factors (Nr4a triple knockout) promoted tumour regression and prolonged the survival of tumour-bearing mice.
|
30814732 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These responses are strictly limited and are tightly linked, since β-catenin is activated in nearly all of the CAR-dependent tumours generated by the tumour promoter phenobarbital.
|
25661872 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The spectral characterisation and unmixing validation studies reported here established that iLH<sub>2</sub> is superior to LH<sub>2</sub> for the spectral unmixing of bioluminescent signals in vivo; which led to this novel near-infrared dual BLI system being applied to monitor both tumour burden and CAR T cell therapy within a systemically induced mouse tumour model.
|
31610848 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intratumoral injection of AxdAdB3-F/RGD into CAR-negative prostate cancer cell xenografts in nude mice inhibited tumor growth.
|
26799485 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because CAR-T cells recognize tumor cells independent of their expression of human leukocyte antigen (HLA) molecules, tumors that escape conventional T cells by downregulating HLA and/or mutating components of the antigen processing machinery can be eliminated.
|
25621840 |
2015 |